SLV308 for Treatment of Patients With Early Parkinson's Disease

NCT00269516 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

468

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Stage Parkinson's Disease

Interventions

DRUG: pardoprunox
DRUG: Pardoprunox
DRUG: Pardoprunox
DRUG: Placebo

Sponsor

Solvay Pharmaceuticals